Pleuropulmonary disease associated with dopamine agonist therapy
- 8 October 1991
- journal article
- case report
- Published by Wiley in Annals of Neurology
- Vol. 30 (4) , 613-616
- https://doi.org/10.1002/ana.410300416
Abstract
Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot‐derived dopamine agonists and pleuropulmonary disease.Keywords
This publication has 12 references indexed in Scilit:
- Bromocriptine and pleuropulmonary diseaseArchives of internal medicine (1960), 1989
- Lisuride Pharmacology and Treatment of Parkinson’s DiseasePublished by Springer Nature ,1989
- Pleuropulmonary disease during bromocriptine treatment of Parkinson's diseaseArchives of internal medicine (1960), 1988
- Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′-beta- carbonyl)-urea-diphosphate (FCE 21336).British Journal of Clinical Pharmacology, 1987
- Retroperitoneal Fibrosis and Treatment of Parkinsonʼs Disease with High Doses of BromocriptineClinical Neuropharmacology, 1986
- Bromocriptine induced pleuropulmonary fibrosis.Thorax, 1986
- Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine.Thorax, 1983
- PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASEThe Lancet, 1981
- Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neuronsJournal of Pharmacy and Pharmacology, 1973
- CARDIAC AND PULMONARY FIBROSIS DURING METHYSERGIDE THERAPY FOR HEADACHEThe Lancet Healthy Longevity, 1967